PredxBio, a biotech company based in Pittsburgh, utilizes spatial biology to uncover the intricate circuitries of the tumor microenvironment. Employing the most advanced form of AI, they achieve over 90% accuracy in discerning the underlying causes of cancer. With a robust pipeline of customers, including pharmaceutical partners, PredxBio’s solutions are instrumental in investigating the diverse responses to therapy observed among patients in clinical trials.
